Finally, serum NfL has been shown to significantly decrease in patients with active forms of MS following 12 months of treatment with disease-modifying therapies that target immune-mediated CNS injury, providing proof-of-concept for NfL as a marker of response to therapy in NDDs [1]. The gene discussed is NEFL; the disease is myeloid sarcoma.